Publications by authors named "R M Mawad"
Article Synopsis
- Acute myeloid leukemia (AML) is an aggressive cancer that currently lacks effective immunotherapy options, making targets like CD123 important for treatment.
- Vibecotamab (XmAb14045) is a bispecific antibody designed to engage T cells to kill CD123+ tumor cells, with a phase 1 study focusing on safety, tolerability, and determining the optimal dosing.
- The study found that 10 out of 111 patients (9.0%) with AML showed a positive response to the treatment, particularly those with lower baseline blast counts, while the most common side effect was cytokine response syndrome, managed with premedication.
Acute Promyelocytic Leukemia (APL) is characterized by the t(15;17) chromosomal translocation resulting in a PML-RARA fusion protein. The all-trans-retinoic acid (ATRA) and Arsenic Trioxide (ATO) only regimens have demonstrated success in treating low- and intermediate-risk patients. However, induction with ATRA/ATO only regimens have been showing increased incidence of differentiation syndrome (DS), a potentially lethal complication, traditionally treated with dexamethasone.
View Article and Find Full Text PDFArticle Synopsis
- - ZUMA-3 is a clinical study testing KTE-X19, a CAR T-cell therapy, for adult patients with relapsed/refractory B-cell acute lymphoblastic leukemia (B-ALL), reporting results from the phase 1 part of the trial.
- - The study involved 45 patients who received a single dose of KTE-X19 after a preparatory regimen, with no dose-limiting toxicities found; however, notable rates of cytokine release syndrome and neurological events occurred.
- - Overall, 83% of patients treated with 1 × 10^6 cells per kg achieved complete remission, with a median remission duration of around 17.6 months; the trial is continuing to phase